Get the Stockscreener App
14.64
8.61%
-1.435
Anaptysbio Inc stock is traded at $14.64, with a volume of 258.02K.
It is down -8.61% in the last 24 hours and down -0.91% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$16.08
Open:
$16.09
24h Volume:
258.02K
Relative Volume:
0.40
Market Cap:
$489.29M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-2.4087
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
-18.04%
1M Performance:
-0.91%
6M Performance:
-53.41%
1Y Performance:
-37.49%
1-Day Range:
$14.57
$16.21
1-Week Range:
$14.57
$17.95
52-Week Range:
$12.51
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
14.64 | 489.29M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.85 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.01 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.13 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.49 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.63 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
Weekly Investment Analysts’ Ratings Updates for AnaptysBio (ANAB) - Defense World
Check Out AnaptysBio Inc (ANAB)’s Trade Data Rather Than the Analysts’ Views - SETE News
Wolfe Research Begins Coverage on AnaptysBio (NASDAQ:ANAB) - Defense World
AnaptysBio (NASDAQ:ANAB) Upgraded at Wolfe Research - Defense World
Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB) - Defense World
H.C. Wainwright maintains AnaptysBio stock Neutral rating, $19 target - MSN
BlackRock, Inc.'s Strategic Acquisition of AnaptysBio Inc Shares - GuruFocus.com
Wedbush Has Bullish Forecast for AnaptysBio Q1 Earnings - MarketBeat
Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago - Yahoo Finance UK
AnaptysBio (NASDAQ:ANAB) Upgraded to "Strong-Buy" at Wolfe Research - MarketBeat
Wolfe Research Initiates Coverage of AnaptysBio (ANAB) with Outperform Recommendation - MSN
What is Wedbush’s Estimate for AnaptysBio FY2029 Earnings? - Defense World
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder - The Business Journals
AnaptysBio initiated with an Outperform at Wolfe Research - MSN
AnaptysBio (NASDAQ:ANAB) Shares Gap UpShould You Buy? - MarketBeat
Analytical Overview: AnaptysBio Inc (ANAB)’s Ratios Tell a Financial Story - The Dwinnex
Wolfe Research Initiates Coverage on AnaptysBio (NASDAQ:ANAB) - MarketBeat
Correction: Wolfe Initiates Coverage on AnaptysBio With Outperform Rating, $25 Price Target - Marketscreener.com
FY2029 Earnings Estimate for AnaptysBio Issued By Wedbush - MarketBeat
AnaptysBio (NASDAQ:ANAB) Given Neutral Rating at HC Wainwright - MarketBeat
Analyzing AnaptysBio Inc (ANAB) After Recent Trading Activity - Knox Daily
(ANAB) Investment Analysis - Stock Traders Daily
Analyst Expectations For AnaptysBio's Future - Benzinga
Vanda and AnaptysBio link for generalised pustular psoriasis therapy - Pharmaceutical Technology
AnaptysBio (NASDAQ:ANAB) Given “Outperform” Rating at Wedbush - Defense World
Vanda Pharmaceuticals and Anaptys sign license agreement for imsidolimab - MSN
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
AnaptysBio (NASDAQ:ANAB) Receives "Outperform" Rating from Wedbush - MarketBeat
Vanda, Anaptys Join on Development Pact - Baystreet.ca
Vanda & AnaptysBio Partner for the Development and Commercialization of Imsidolimab - Contract Pharma
AnaptysBio Partners with Vanda for Imsidolimab Development - TipRanks
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab - Marketscreener.com
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab - TipRanks
AnaptysBio, Vanda announce exclusive global license agreement for Vanda - TipRanks
Breakthrough GPP Treatment Deal: Vanda Secures Phase 3-Ready Rare Disease Drug for $15M Upfront - StockTitan
Indo-Asian News Service - IANS India Pvt Ltd
AnaptysBio (NASDAQ:ANAB) Trading Down 4.5%Should You Sell? - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by JPMorgan Chase & Co. - MarketBeat
JPMorgan Chase & Co. Increases Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Objective long/short (ANAB) Report - Stock Traders Daily
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Assenagon Asset Management S.A. Cuts Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Assenagon Asset Management S.A. Decreases Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Shareholders May Not Overlook AnaptysBio Insiders Selling US$3.6m In Stock - Simply Wall St
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry - Yahoo Finance
Barclays PLC Grows Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Anaptysbio announces clearance of U.S., India, U.K. CTA for ANB020 - Reuters
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anaptysbio Inc Stock (ANAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
Dec 30 '24 |
Buy |
12.92 |
65,184 |
842,060 |
7,860,180 |
| EcoR1 Capital, LLC | Director |
Dec 31 '24 |
Buy |
12.93 |
13,268 |
171,513 |
7,873,448 |
| EcoR1 Capital, LLC | Director |
Jan 02 '25 |
Buy |
12.95 |
6,646 |
86,070 |
7,880,094 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Option Exercise |
6.93 |
10,000 |
69,300 |
11,950 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Sale |
25.00 |
10,000 |
250,000 |
1,950 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):